European regulators approve new Parkinson's and Rett syndrome treatments while revoking an autoimmune drug and reviewing tuberculosis medication safety concerns.

The EMA approved a new levodopa-carbidopa combination formulation designed to treat moderate-to-severe motor fluctuations in Parkinson's disease patients by combining immediate and slow-release mechanisms for improved symptom management.

Trofinetide received EMA marketing authorization for Rett syndrome after a reexamination reversed the agency's previous rejection, making it the world's first drug specifically approved to treat this rare genetic neurological disorder.

The EMA revoked approval of Tavneos for treating active granulomatosis with polyangiitis after new data indicated the risks of the autoimmune disease drug no longer justified its benefits.

European regulators initiated a safety review of Rifadin tuberculosis syrup following carcinogen concerns raised by the Dutch medicines agency, potentially affecting treatment options for TB patients.

uniQure's gene therapy AMT-130 for Huntington's disease faces regulatory challenges, with the company considering seeking UK approval first while negotiating with the FDA over requirements for a larger, sham-controlled trial.

A Pfizer post-marketing trial confirmed that Paxlovid achieves effective blood concentrations in high-risk children aged 6 years and older with mild-to-moderate COVID-19, supporting its use in pediatric populations.

Data from EULAR 2026 revealed that one-third of rheumatic disease patients experience severe, unresolved chronic pain 15 years after diagnosis, exposing a significant treatment gap in current anti-inflammatory protocols.

Home-based human papillomavirus screening for cervical cancer demonstrates modest uptake in diverse community settings, suggesting barriers to adoption of this convenient alternative to clinic-based screening.